Tonix Pharmaceuticals, Bilthoven announce collaboration to advance TNX-801

Tonix Pharmaceuticals and Bilthoven Biologicals announced a collaboration to advance TNX-801, Tonix’s mpox vaccine candidate. TNX-801 is a live replicating, attenuated virus vaccine based on horsepox in preclinical development to prevent mpox and smallpox. “The recent mpox outbreak exemplifies precisely why we built the pandemic preparedness facility at BBio,” said Jurgen Kwik, Chief Executive Officer of Bilthoven Biologicals. “The establishment of the ‘ever-warm’ facility for pandemic preparedness underscores the critical importance of readiness in the face of global health emergencies, such as mpox. This collaboration encapsulates the essential role of the facility in bolstering pandemic preparedness and response capabilities.”